The Design and Rationale of a Phase 2b, Randomized, Double-Blinded, and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Lomecel-B in Older Adults with Frailty.

Yousefi, K; Ramdas, K N; Ruiz, J G; Walston, J; Arai, H; Volpi, E; Newman, A B; Wang, C; Hitchinson, B; McClain-Moss, L; Diaz, L; Green, G A; Hare, J M; Oliva, A A

Yousefi, K; Ramdas, K N; Ruiz, J G; Walston, J; Arai, H; Volpi, E; Newman, A B; Wang, C; Hitchinson, B; McClain-Moss, L; Diaz, L; Green, G A; Hare, J M; Oliva, A A.

Affiliation

Yousefi K; Anthony A. Oliva, Longeveron Inc. 1951 NW 7th Ave., Suite 520, Miami, FL 33136, USA; aoliva@longeveron.com.

J Frailty Aging ; 11(2): 214-223, 2022.

Article in En | MEDLINE | ID: mdl-35441200

Subject(s)

COVID-19; Frailty; Aged; Biomarkers; Double-Blind Method; Humans; SARS-CoV-2; Treatment Outcome

Key words

6-minute walk test; Frailty; medicinal signaling cell; mesenchymal stem cells; physical function

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Frailty / COVID-19 Type of study: Clinical_trials Aspects: Patient_preference Limits: Aged / Humans Language: En Journal: J Frailty Aging Year: 2022 Document type: Article Country of publication: France

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google